← Back to Clinical Trials
Recruiting NCT07618676

NCT07618676 The 50:50 Nitrous Oxide vs 2% Lidocaine Challenge

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07618676
Status Recruiting
Phase
Sponsor Institute for Oncology and Radiology of Serbia
Condition Acute Pain
Study Type INTERVENTIONAL
Enrollment 62 participants
Start Date 2025-06-06
Primary Completion 2026-06-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Nitrous Oxide-OxygenLidocaine 2% Injectable Solution

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 62 participants in total. It began in 2025-06-06 with a primary completion date of 2026-06-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main goal of the project is to assess pain levels and patient comfort during the administration of a 50:50 Nitrous Oxide/Oxygen gas mixture, in comparison to the same parameters under the standard method used at our institution, which includes injecting a local anaesthetic at the site of planned puncture for central venous catheterisation.

Eligibility Criteria

Inclusion Criteria: * Subjects who have not previously received Nitrous Oxide. * Subjects of both sexes, aged between 18 and 65 inclusive. * Subjects who have signed informed consent with full disclosure; no study-related procedure may begin until the subject signs the consent form. Exclusion Criteria: * Infection at the planned puncture site. * Pregnancy. * Intracranial hypertension. * Vitamin B12 deficiency. * Hemodynamic instability. * BMI over 35. * Glasgow Coma Scale (GCS) score less than 15. * Presence of chronic pain. * Neurological disorders. * Hematologic disorders. * More than two attempts at venous puncture (Subject Withdrawal Criterion). * Subject experienced an adverse event requiring early discontinuation (Subject Withdrawal Criterion). * Withdrawal of consent by the subject (Subject Withdrawal Criterion)

Contact & Investigator

Central Contact

Ana Cvetkovic, MD,PhD

✉ ana.cvetkovic@ncrc.ac.rs

📞 +381 11 2067 100

Principal Investigator

Ana Cvetković, MD, PhD

PRINCIPAL INVESTIGATOR

Institute for Oncology and Radiology of Serbia

Frequently Asked Questions

Who can join the NCT07618676 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Acute Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07618676 currently recruiting?

Yes, NCT07618676 is actively recruiting participants. Contact the research team at ana.cvetkovic@ncrc.ac.rs for enrollment information.

Where is the NCT07618676 trial being conducted?

This trial is being conducted at Belgrade, Serbia.

Who is sponsoring the NCT07618676 clinical trial?

NCT07618676 is sponsored by Institute for Oncology and Radiology of Serbia. The principal investigator is Ana Cvetković, MD, PhD at Institute for Oncology and Radiology of Serbia. The trial plans to enroll 62 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology